about
HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy.Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines.Immunodominance of lytic cycle antigens in Epstein-Barr virus-specific CD4+ T cell preparations for therapyConditional immortalization of human B cells by CD40 ligation.The EBV immunoevasins vIL-10 and BNLF2a protect newly infected B cells from immune recognition and eliminationExpression of the human cytomegalovirus UL11 glycoprotein in viral infection and evaluation of its effect on virus-specific CD8 T cells.Activated human gammadelta T cells as stimulators of specific CD8+ T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer.Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells.Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins.Engineering antigen-specific primary human NK cells against HER-2 positive carcinomasEpstein-Barr viral miRNAs inhibit antiviral CD4+ T cell responses targeting IL-12 and peptide processing.Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.CD8 T cell-evasive functions of human cytomegalovirus display pervasive MHC allele specificity, complementarity, and cooperativity.Suppression of CD8+ T-cell recognition in the immediate-early phase of human cytomegalovirus infection.Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus.A synthetic human cytomegalovirus pp65-IE1 fusion antigen efficiently induces and expands virus specific T cells.Genetic design of an optimized packaging cell line for gene vectors transducing human B cells.Occurrence, risk factors and outcome of adenovirus infection in adult recipients of allogeneic hematopoietic stem cell transplantation.A Diverse Repertoire of CD4 T Cells Targets the Immediate-Early 1 Protein of Human Cytomegalovirus.Virus infection in HLA-haploidentical hematopoietic stem cell transplantation: incidence in the context of immune recovery in two different transplantation settings.Effective and long-term control of EBV PTLD after transfer of peptide-selected T cells.Mature proteins derived from Epstein-Barr virus fail to feed into the MHC class I antigenic pool.Epstein-Barr virus strain heterogeneity impairs human T-cell immunity.Characterization and clinical enrichment of HLA-C*07:02-restricted Cytomegalovirus-specific CD8+ T cells.CMV-specific TCR-transgenic T cells for immunotherapy.Specific CD8⁺ T cells recognize human herpesvirus 6B.Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts.Cross-sectional analysis of CD8 T cell immunity to human herpesvirus 6B.Activated B cells mediate efficient expansion of rare antigen-specific T cellsImmune restoration in head and neck cancer patients after in vivo COX-2 inhibitionA central role of IKK2 and TPL2 in JNK activation and viral B-cell transformationAntigen-Specific TCR Signatures of Cytomegalovirus InfectionCytomegalovirus inhibition of extrinsic apoptosis determines fitness and resistance to cytotoxic CD8 T cells
P50
Q33215800-DD728C6C-347C-4615-A0A2-EBBF1667F252Q33217629-C63C26EC-C508-496C-A835-490032C8C6B2Q33289956-256EADB5-C668-4323-9B2A-FF93A57F210AQ33316020-7687C1A8-7C96-475E-AEE3-30A0D3CF3B76Q34277034-795BBDC0-6C84-4AAD-AF32-F0C94981C7ABQ34594928-54CF26A1-A3B1-4D4D-8904-ED2317067307Q35222179-19E1ECC6-1BA3-42B1-9DB1-E17FE73F1F39Q35661383-5DA183BC-2785-4EFC-9D2E-11D5BE4C3B08Q36228567-55C0BFFC-6E86-43CB-8F92-D0E4484F9A17Q36970863-1BE2D2FD-EB11-45A0-9F98-214D8BD61C31Q37272108-D27B994C-3196-41CC-8E46-A50924FB2995Q37369220-DEA66392-CFB5-46DD-8608-510804767948Q38997215-DF714A11-DB95-43D8-9497-5D2FC489BFAFQ39253077-343E14D2-CCFF-45E6-A08C-4D4714BC940FQ39609877-976018EA-EE6C-43B5-AD57-551AD34E55CDQ40079187-B6BFD583-5C84-4A3C-8A51-47438C8E71FCQ40327889-4A88CEC9-6DF3-49DE-8624-636BF0D49621Q40610037-5D24985B-1969-4BFB-81B9-236DC1834FBCQ40883276-150AC6D9-D2F5-44FC-AFC1-719B2B1BB87DQ41175701-3BFF6B22-D3C9-42A3-83EF-55F5C4EC9F9BQ44013424-55510F8E-1227-4EBA-8FF1-B33956A91E22Q45355050-84B7690E-E6A8-47B5-9FA0-64A8682395EAQ47548563-A9DD296D-EAF4-4604-9DDA-8C1387346D71Q50533781-9B6BFAE4-BA01-4A34-92CD-DF8FA888826EQ51889453-ED9F63A3-FFCC-49EC-B194-8023F7BF6148Q54296983-0E04B71E-0216-4BB8-8FD9-98B2DF6CFA7FQ55259946-523AE8F8-9444-4D78-A440-967CA4D6BFE6Q55342452-A3D2F991-CC4B-47BD-8699-31591C6A31A7Q79829633-86C2960A-0F54-4601-A1C5-75F8779DEFEFQ80044869-7B4E1ABA-7450-4919-8C9D-22019405A905Q89531869-F40A0394-DB52-40D4-B360-629CDA2D1A04Q90764131-A961A771-5F73-4E7F-8956-EFA07EB53EA3Q95659734-F16B6CE5-6DCE-498D-A3BF-D6A14CD3DD4D
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Andreas Moosmann
@ast
Andreas Moosmann
@en
Andreas Moosmann
@es
type
label
Andreas Moosmann
@ast
Andreas Moosmann
@en
Andreas Moosmann
@es
prefLabel
Andreas Moosmann
@ast
Andreas Moosmann
@en
Andreas Moosmann
@es
P106
P1153
8646440800
P21
P31
P496
0000-0001-8044-5146